Supercharged immune cells take on Hard-to-Treat blood cancers
NCT ID NCT00881920
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new type of immune therapy for people with certain blood cancers (CLL, lymphoma, or multiple myeloma) that have come back or not responded to treatment. Researchers take a patient's own T cells, add a special receptor that targets a protein called kappa on cancer cells, and also add a growth booster (CD28) to help the cells last longer. The goal is to see if these modified cells are safe and can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Kappa-CD28 T cells (engineered immune cells)
What this could lead to
If successful, this could lead to a new treatment option for patients with certain blood cancers that have not responded to standard therapies.
What could go wrong
This is an early phase 1 trial with only 54 participants, so results may not apply to everyone. The cells may not last long in the body or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States